Richard Kuntz joins Tengion's board
This article was originally published in Clinica
Executive Summary
Regenerative medicine specialist Tengion has appointed Richard Kuntz to its board of directors. Dr Kuntz is currently Medtronic's senior vice-president and chief scientific, clinical and regulatory officer. Before joining Medtronic in 2005, he was founder and chief scientific officer of the Harvard Clinical Research Institute, a contract research organisation based at the university. Dr Kuntz has directed over 100 multicentre clinical trials and has authored more than 200 scientific papers, and has experience in developing both pharmaceuticals and medical devices. East Norriton, Pennsylvania-based Tengion's technology is designed to regenerate organs and tissues from patients' own cells. Its most advanced product is the Neo-Bladder Augment, which has completed two Phase II trials in patients with neurogenic bladder (when the nerves controlling bladder function do not work properly).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.